Case number 2017-2473
Nuvo Pharmaceuticals v. Dr. Reddy's Laboratories Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | NUVO PHARMACEUTICALS v. DR. REDDY'S LABORATORIES INC. [OPINION - PRECEDENTIAL] [precedential] (0) |
| Jan 16, 2020 | 124 | The petition for writ of certiorari, [19-584], filed on 10/28/2019, was Denied on 01/13/2020. [663594] [JAB] [Entered: 01/16/2020 07:51 AM] (1) |
| Nov 5, 2019 | 123 | Petition for writ of Certiorari filed on 10/28/2019, and placed on the docket 11/04/2019, in the Supreme Court of the United States. Supreme Court #: 19-584, Nuvo Pharmaceuticals (Ireland) Designated Activity Company, et al. v. Dr. Reddy's Laboratories Inc., et al. [647331] [JAB] [Entered: 11/06/2019 12:59 PM] (1) |
| Aug 6, 2019 | 121 | ORDER filed denying [120] motion to stay mandate filed by Nuvo Pharmaceuticals (Ireland) Designated Activity Company and Horizon Medicines LLC. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [626424] [JAB] [Entered: 08/06/2019 04:01 PM] (2) |
| Aug 6, 2019 | 122 | Mandate issued to the United States District Court for the District of New Jersey. Service as of this date by the Clerk of Court. [626426] [17-2473, 17-2481, 17-2484, 17-2486, 17-2489, 17-2491, 17-2492, 17-2493] [JAB] [Entered: 08/06/2019 04:04 PM] (2) |
| Aug 5, 2019 | 120 | MOTION of Cross-Appellants Horizon Medicines LLC and Nuvo Pharmaceuticals (Ireland) Designated Activity Company to stay execution of the mandate until Horizon and Nuvo file their petition for writ of certiorari which must be filed by October 28, 2019, with a continuance of the stay to follow when Horizon and Nuvo file the petition and so notify the Clerk the petition has been filed. [Consent: opposed]. Service: 08/05/2019 by email. [626122] [17-2473] [Charles Collins-Chase] [Entered: 08/05/2019 07:24 PM] (20) |
| Jul 30, 2019 | 119 | ORDER filed denying [112] petition for en banc rehearing filed by Nuvo Pharmaceuticals (Ireland) Designated Activity Company and Horizon Medicines LLC. By: En Banc (Per Curiam). Service as of this date by the Clerk of Court. [624361] [JAB] [Entered: 07/30/2019 08:26 AM] (2) |
| Jul 16, 2019 | 118 | 18 paper copies of the response [117] received from Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, Ltd. [621318] [JAB] [Entered: 07/16/2019 12:53 PM] (0) |
| Jul 15, 2019 | 117 | RESPONSE of Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, Ltd. to the petition for en banc rehearing [112] filed by Cross-Appellants Horizon Medicines LLC and Nuvo Pharmaceuticals (Ireland) Designated Activity Company. Service: 07/15/2019 by email. [620881] [17-2473] [Alan Pollack] [Entered: 07/15/2019 12:38 PM] (21) |
| Jul 1, 2019 | 116 | The court invites a combined response from Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Mylan, Inc. and Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc. to the petition for en banc rehearing filed by Cross-Appellants in 17-2473. The response is due on or before 07/15/2019. [618322] [JAB] [Entered: 07/01/2019 04:14 PM] (1) |
| Jun 25, 2019 | 115 | ORDER filed. The motion [114] filed by Mylan Pharmaceuticals Inc., Mylan, Inc. and Mylan Laboratories Limited is denied. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [616788] [JAB] [Entered: 06/25/2019 01:51 PM] (2) |
| Jun 21, 2019 | 114 | MODIFIED ENTRY: MOTION of Appellants Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc. to withdraw party, Myan Inc., Mylan Pharmaceuticals Inc., Mylan Laboratories Ltd., as a party to this appeal [Consent: partial consent]. Service: 06/21/2019 by clerk. [615939]--[Edited 06/24/2019 by JAB to correct relief] [Andrew Dufresne] [Entered: 06/21/2019 08:28 AM] (5) |
| Jun 18, 2019 | 113 | 18 paper copies of the petition for en banc rehearing [112] received from Cross-Appellants Horizon Medicines LLC and Nuvo Pharmaceuticals (Ireland) Designated Activity Company. [614997] [JAB] [Entered: 06/18/2019 10:20 AM] (0) |
| Jun 14, 2019 | 112 | Petition for en banc rehearing filed by Cross-Appellants Horizon Medicines LLC and Nuvo Pharmaceuticals (Ireland) Designated Activity Company. Service: 06/14/2019 by email. The paper copies of the petition must be filed within two business days (see Fed. Cir. R. 35(c)(4).The required paper copies should be received by the court on or before 06/18/2019 [614465] [17-2473] [Charles Collins-Chase] [Entered: 06/14/2019 07:28 PM] (54) |
| May 15, 2019 | 110 | OPINION filed for the court by Prost, Chief Judge; Clevenger, Circuit Judge and Wallach, Circuit Judge. Precedential Opinion. [607400] [17-2473, 17-2481, 17-2484, 17-2486, 17-2489, 17-2491, 17-2492, 17-2493] [JAB] [Entered: 05/15/2019 09:42 AM] (25) |
| May 15, 2019 | 111 | JUDGMENT filed. REVERSED as to 17-2473, 17-2481, 17-2484, 17-2486; DISMISSED as to 17-2489, 17-2491, 17-2492, 17-2493. Terminated on the merits after oral argument. COSTS: No Costs. Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [607402] [17-2473, 17-2481, 17-2484, 17-2486, 17-2489, 17-2491, 17-2492, 17-2493] [JAB] [Entered: 05/15/2019 09:44 AM] (2) |
| May 8, 2019 | 109 | ORDER filed. The motion [108] is granted to the extent that: (1) 17-2487 and 17-2488 are deconsolidated from 17-2473, consolidated together, and stayed; (2) The parties to 17-2487, -2488 shall file a joint status report within 30 days; (3) The revised official captions are reflected in the order. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [605764] [17-2473, 17-2487, 17-2488] [JAB] [Entered: 05/08/2019 10:01 AM] (3) |
| May 1, 2019 | 108 | MOTION of Cross-Appellants Horizon Medicines LLC, Nuvo Pharmaceuticals (Ireland) Designated Activity Company and Appellants Lupin Ltd. and Lupin Pharmaceuticals, Inc. to stay appeal [Consent: unopposed]. Service: 05/01/2019 by email. [604519] [17-2473] [Charles Collins-Chase] [Entered: 05/01/2019 09:40 PM] (13) |
| Apr 18, 2019 | 107 | Amended Entry of appearance for Alan H. Pollack as principal counsel for Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, Ltd.. Service: 04/18/2019 by email. [601244] [17-2473] [Alan Pollack] [Entered: 04/18/2019 12:01 PM] (1) |
| Apr 10, 2019 | 106 | Amended Certificate of Interest for the Cross-Appellant Horizon Medicines LLC. Service: 04/10/2019 by email. [599056] [17-2473] [Charles Collins-Chase] [Entered: 04/10/2019 03:22 PM] (3) |
| Apr 9, 2019 | 105 | Submitted after ORAL ARGUMENT by Andrew Dufresne for Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc., Mr. Alan Henry Pollack, Esq. for Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc. and Mr. James B. Monroe for Horizon Medicines LLC and Nuvo Pharmaceuticals (Ireland) Designated Activity Company. Panel: Judge: Prost , Judge: Clevenger , Judge: Wallach. [598633] [JCP] [Entered: 04/09/2019 10:30 AM] (0) |
| Apr 1, 2019 | 104 | ORDER filed granting motion to modify the official caption [103] filed by Cross-Appellant Horizon Pharma, Inc. The revised official caption is reflected in the order. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [596682] [JAB] [Entered: 04/01/2019 08:50 AM] (2) |
| Mar 27, 2019 | 101 | MOTION of Cross-Appellant Horizon Pharma, Inc. to modify the official caption [Consent: unopposed]. Service: 03/27/2019 by email. [595901] [17-2473] This document is non-compliant. See Doc. No. [102]. [Charles Collins-Chase] [Entered: 03/27/2019 02:13 PM] (8) |
| Mar 27, 2019 | 102 | NOTICE OF NON-COMPLIANCE: The submission of Cross-Appellant Horizon Pharma, Inc., Motion to Reform the Official Caption [101], is not in compliance with the rules of this court (see attached). Service as of this date by the Clerk of Court. [595934] [JAB] [Entered: 03/27/2019 03:06 PM] (1) |
| Mar 27, 2019 | 103 | MOTION of Cross-Appellant Horizon Pharma, Inc. to modify the official caption [Consent: unopposed]. Service: 03/27/2019 by email. [595982] [17-2473] [Charles Collins-Chase] [Entered: 03/27/2019 04:14 PM] (8) |
| Mar 18, 2019 | 100 | Response to notice of oral argument from the Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. [593538] [17-2473] [Alan Pollack] [Entered: 03/18/2019 11:45 AM] (3) |
| Mar 15, 2019 | 96 | ORDER filed. Oral argument is rescheduled for April 9, 2019 at 10:00 a.m. in Courtroom 201. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [593100] [JAB] [Entered: 03/15/2019 10:14 AM] (2) |
| Mar 15, 2019 | 97 | NOTICE OF ORAL ARGUMENT. Panel: 1904P. Case scheduled Apr 09, 2019 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 201. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [593102] [JAB] [Entered: 03/15/2019 10:18 AM] (2) |
| Mar 15, 2019 | 98 | Response to notice of oral argument from the Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. [593228] [17-2473] [Andrew Dufresne] [Entered: 03/15/2019 02:12 PM] (2) |
| Mar 15, 2019 | 99 | Response to notice of oral argument from the Cross-Appellants Horizon Pharma, Inc. and Nuvo Pharmaceuticals (Ireland) Designated Activity Company. [593377] [17-2473] [Charles Collins-Chase] [Entered: 03/15/2019 06:10 PM] (3) |
| Mar 13, 2019 | 94 | Response to notice of oral argument from the Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. [592453] [17-2473] [Alan Pollack] [Entered: 03/13/2019 10:23 AM] (3) |
| Mar 13, 2019 | 95 | Response to notice of oral argument from the Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. [592706] [17-2473] [Andrew Dufresne] [Entered: 03/13/2019 10:30 PM] (2) |
| Mar 4, 2019 | 93 | NOTICE OF ORAL ARGUMENT. Panel: 1904P. Case scheduled Apr 05, 2019 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 402. Response to Notice of Oral Argument due: 03/15/2019. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [590132] [JAB] [Entered: 03/04/2019 03:39 PM] (2) |
| Feb 25, 2019 | 92 | ORDER filed granting motion to reschedule argument [91] filed by Cross-Appellants Horizon Pharma, Inc. and Nuvo Pharmaceuticals (Ireland) Designated Activity Company in 17-2473. By: Per Curiam. Service as of this date by the Clerk of Court. [588252] [17-2473, 17-2481, 17-2484, 17-2486, 17-2487, 17-2488, 17-2489, 17-2491, 17-2492, 17-2493] [PBC] [Entered: 02/25/2019 09:19 AM] (2) |
| Feb 22, 2019 | 91 | MOTION of Cross-Appellants Horizon Pharma, Inc. and Nuvo Pharmaceuticals (Ireland) Designated Activity Company to reschedule argument [Consent: unopposed]. Service: 02/22/2019 by email. [588056] [17-2473] [Charles Collins-Chase] [Entered: 02/22/2019 02:54 PM] (10) |
| Feb 19, 2019 | 90 | Response to notice of oral argument from the Cross-Appellants Horizon Pharma, Inc. and Nuvo Pharmaceuticals (Ireland) Designated Activity Company. [586753] [17-2473] [Charles Collins-Chase] [Entered: 02/17/2019 03:34 PM] (3) |
| Feb 15, 2019 | 88 | Response to notice of oral argument from the Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. [586352] [17-2473] [Andrew Dufresne] [Entered: 02/15/2019 12:31 PM] (2) |
| Feb 15, 2019 | 89 | Response to notice of oral argument from the Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. [586505] [17-2473] [Alan Pollack] [Entered: 02/15/2019 03:28 PM] (3) |
| Jan 22, 2019 | 87 | NOTICE OF ORAL ARGUMENT. Panel: 1903C. Case scheduled Mar 04, 2019 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 402. Response to Notice of Oral Argument due: 02/15/2019. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [579704] [JAB] [Entered: 01/22/2019 01:22 PM] (2) |
| Jan 15, 2019 | 81 | ORDER filed. The motion [78] is granted. The revised official caption is reflected in the order. Service: 01/15/2019 by clerk. [578059] [LMS] [Entered: 01/15/2019 11:08 AM] (2) |
| Jan 15, 2019 | 82 | Corrected Entry of appearance for Jeffrey S. Gritton as of counsel for Cross-Appellant Nuvo Pharmaceuticals (Ireland) Designated Activity Company. Service: 01/15/2019 by email. [578108] [17-2473] [Jeffrey Gritton] [Entered: 01/15/2019 12:51 PM] (2) |
| Jan 15, 2019 | 83 | Corrected Entry of appearance for Stephen M. Hash as principal counsel for Cross-Appellant Nuvo Pharmaceuticals (Ireland) Designated Activity Company. Service: 01/15/2019 by email. [578110] [17-2473] [Stephen Hash] [Entered: 01/15/2019 12:56 PM] (2) |
| Jan 15, 2019 | 84 | NOTICE OF NON-COMPLIANCE: The submission of Cross-Appellant Nuvo Pharmaceuticals (Ireland) Designated Activity Company, Certificate of Interest [77], is not in compliance with the rules of this court (see attached). Compliant document due on 01/22/2019. Service as of this date by the Clerk of Court.[578141] [JAL] [Entered: 01/15/2019 02:18 PM] (1) |
| Jan 15, 2019 | 85 | Notice from Cross-Appellant Nuvo Pharmaceuticals (Ireland) Designated Activity Company regarding conflicts with oral argument. None. Service: 01/15/2019 by email. [578146] [17-2473] [Stephen Hash] [Entered: 01/15/2019 02:28 PM] (2) |
| Jan 15, 2019 | 86 | Corrected Certificate of Interest for the Cross-Appellant Nuvo Pharmaceuticals (Ireland) Designated Activity Company. Service: 01/15/2019 by email. [578174] [17-2473] [Stephen Hash] [Entered: 01/15/2019 03:20 PM] (3) |
| Jan 14, 2019 | 76 | Entry of appearance for Stephen M. Hash as principal counsel for Cross-Appellant Nuvo Pharmaceuticals (Ireland) Limited. Service: 01/14/2019 by email. [577977] [17-2473] [Stephen Hash] [Entered: 01/14/2019 06:46 PM] (2) |
| Jan 14, 2019 | 77 | Certificate of Interest for the Cross-Appellant Nuvo Pharmaceuticals (Ireland) Limited. Service: 01/14/2019 by email. [577978] [17-2473] This document is non-compliant. See Doc No.[84] [Stephen Hash] [Entered: 01/14/2019 06:49 PM] (3) |
| Jan 14, 2019 | 78 | MOTION of Nuvo Pharmaceuticals (Ireland) Designated Activity Company Cross-Appellant Nuvo Pharmaceuticals (Ireland) Limited to substitute party [Consent: unopposed]. Service: 01/14/2019 by email. [577979] [17-2473] [Stephen Hash] [Entered: 01/14/2019 07:03 PM] (113) |
| Jan 14, 2019 | 79 | Entry of appearance for Jeffrey S. Gritton as of counsel for Cross-Appellant Nuvo Pharmaceuticals (Ireland) Limited Nuvo Pharmaceuticals (Ireland) Designated Activity Company. Service: 01/14/2019 by email. [577980] [17-2473] [Jeffrey Gritton] [Entered: 01/14/2019 07:16 PM] (2) |
| Jan 14, 2019 | 80 | Notice from Cross-Appellant Horizon Pharma, Inc. regarding conflicts with oral argument. None. Service: 01/14/2019 by email. [577984] [17-2473] [Charles Collins-Chase] [Entered: 01/14/2019 10:15 PM] (3) |
| Jan 9, 2019 | 73 | ORDER filed. The stay is lifted. The revised official caption is reflected in the order. No later than end of day Monday, January 14, 2019, Nuvo Pharmaceuticals is directed to file an entry of appearance for an attorney on its behalf, its certificate of interest, and to inform the court as to how it believes these appeals should proceed, including advising the clerk of court of scheduling conflicts for the next three court weeks. Service: 01/09/2019 by clerk. [577055] [LMS] [Entered: 01/09/2019 03:20 PM] (2) |
| Jan 9, 2019 | 74 | MOTION of Appellants Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc. to withdraw counsel Robert D. Swanson [Consent: unopposed]. Service: 01/09/2019 by clerk. [577097] [17-2473] [Andrew Dufresne] [Entered: 01/09/2019 04:20 PM] (5) |
| Jan 9, 2019 | 75 | **TEXT ONLY** ORDER granting motion to withdraw Robert D. Swanson as counsel [74] filed by Appellants Mylan Pharmaceuticals Inc., Mylan, Inc. and Mylan Laboratories Limited. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [577101] [JAL] [Entered: 01/09/2019 04:27 PM] (0) |
| Jan 4, 2019 | 72 | RESPONSE of Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc. to the court order to stay appeal [69] , court order [69]. Service: 01/04/2019 by email. [576059] [17-2473] [Dan Bagatell] [Entered: 01/04/2019 04:20 PM] (279) |
| Dec 28, 2018 | 70 | Amended Entry of appearance for Andrew T. Dufresne as of counsel for Appellants Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. Service: 12/28/2018 by clerk. [574939] [17-2473] [Andrew Dufresne] [Entered: 12/28/2018 11:46 AM] (1) |
| Dec 28, 2018 | 71 | Amended Entry of appearance for Autumn N. Nero as of counsel for Appellants Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. Service: 12/28/2018 by clerk. [574947] [17-2473] [Autumn Nero] [Entered: 12/28/2018 12:17 PM] (1) |
| Sep 12, 2018 | 69 | ORDER filed staying appeal. The parties are directed to notify the court within 10 days of the bankruptcy court’s ruling on any motion regarding the application of the automatic stay as to this appeal, or any other developments affecting whether the appeal may proceed. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [549226] [JAB] [Entered: 09/12/2018 03:04 PM] (2) |
| Sep 10, 2018 | 67 | RESPONSE of Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc. to the party letter [64] filed by Cross-Appellant Pozen Inc.. Service: 09/10/2018 by clerk. [548572] [17-2473] [Andrew Dufresne] [Entered: 09/10/2018 05:07 PM] (5) |
| Sep 10, 2018 | 68 | RESPONSE of Cross-Appellant Horizon Pharma, Inc. to the party letter [64] filed by Cross-Appellant Pozen Inc.. Service: 09/10/2018 by email. [548597] [17-2473] [Charles Collins-Chase] [Entered: 09/10/2018 07:28 PM] (6) |
| Aug 30, 2018 | 66 | ORDER filed. The appeals are stayed as to Pozen Inc. Oral argument is cancelled. Response to [64] party letter due 09/10/2018. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [546338] [SJ] [Entered: 08/30/2018 10:31 AM] (2) |
| Aug 29, 2018 | 65 | Amended Certificate of Interest for the Cross-Appellant Horizon Pharma, Inc.. Service: 08/29/2018 by email. [546273] [17-2473] [Charles Collins-Chase] [Entered: 08/29/2018 07:13 PM] (3) |
| Aug 27, 2018 | 64 | Notice regarding bankruptcy (Plaintiff-Cross-Appellant Pozen Inc.'s Suggestion of Bankruptcy) from Cross-Appellant Pozen Inc.. Service: 08/27/2018 by email. [545698] [17-2473] [Stephen Hash] [Entered: 08/27/2018 04:51 PM] (5) |
| Aug 21, 2018 | 63 | NOTICE OF CALENDARING. Panel: 1810D. Case scheduled Oct 03, 2018 10:00 a.m. at the Northwestern University Pritzker School of Law (375 East Chicago Avenue, Chicago, IL 60611), Thorne Auditorium, 1st Floor. Response to oral argument order due: 09/17/2018. Arguing counsel must check-in 30 minutes prior to the opening of the session. Please review the Oral Argument Order. [544321]--[Edited 08/21/2018 by JAB to correct address] [JAB] [Entered: 08/21/2018 11:44 AM] (0) |
| Jun 28, 2018 | 62 | Notice from Appellants Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc. regarding conflicts with oral argument (September 7, 2018 and December 3-7, 2018). Service: 06/28/2018 by clerk. [532597] [17-2473] [Andrew Dufresne] [Entered: 06/28/2018 03:44 PM] (3) |
| Apr 18, 2018 | 59 | Notice from Appellants Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc. regarding conflicts with oral argument (December 3-7, 2018). Service: 04/18/2018 by clerk. [515040] [17-2473] [Andrew Dufresne] [Entered: 04/18/2018 06:09 PM] (3) |
| Apr 18, 2018 | 60 | Notice from Cross-Appellant Horizon Pharma, Inc. regarding conflicts with oral argument (June 4-8; July 9; July 12-13 and August 6-10). Service: 04/18/2018 by email. [515080] [17-2473] [Charles Collins-Chase] [Entered: 04/18/2018 10:00 PM] (7) |
| Apr 18, 2018 | 61 | 6 paper copies of the Confidential Joint Appendix in 2 Volumes [55] received from Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc. [515086] [JCP] [Entered: 04/19/2018 07:41 AM] (0) |
| Apr 12, 2018 | 58 | 6 paper copies of the Reply Brief [49] received from Cross-Appellants Horizon Pharma, Inc. and Pozen Inc. [512794] [JCP] [Entered: 04/12/2018 10:29 AM] (0) |
| Apr 11, 2018 | 57 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks, or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 04/18/2018. [512589] [JB] [Entered: 04/11/2018 04:04 PM] (0) |
| Apr 9, 2018 | 50 | TENDERED from Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Mylan, Inc. and Cross-Appellants Horizon Pharma, Inc. and Pozen Inc.. Title: JOINT APPENDIX. Service: 04/09/2018 by email. [511880] [17-2473] [Dan Bagatell] [Entered: 04/09/2018 08:54 PM] (1020) |
| Apr 9, 2018 | 51 | TENDERED from Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Mylan, Inc. and Cross-Appellants Horizon Pharma, Inc. and Pozen Inc.. Title: CONFIDENTIAL JOINT APPENDIX Service: 04/09/2018 by email. [511881] [17-2473] [Dan Bagatell] [Entered: 04/09/2018 09:06 PM] (0) |
| Apr 9, 2018 | 52 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. Service: 04/09/2018 by email. [511882] [17-2473] [Dan Bagatell] [Entered: 04/09/2018 09:09 PM] (3) |
| Apr 9, 2018 | 53 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Mylan, Inc. and Cross-Appellants Horizon Pharma, Inc. and Pozen Inc.. Service: 04/09/2018 by email. [511884] [17-2473] [Dan Bagatell] [Entered: 04/09/2018 09:11 PM] (3) |
| Apr 9, 2018 | 54 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Cross-Appellants Horizon Pharma, Inc. and Pozen Inc.. Service: 04/09/2018 by email. [511892] [17-2473] [Charles Collins-Chase] [Entered: 04/09/2018 10:03 PM] (7) |
| Apr 9, 2018 | 55 | CONFIDENTIAL JOINT APPENDIX FILED for Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Mylan, Inc. and Horizon Pharma, Inc. and Pozen Inc. [51]. Number of Pages: 1043. Service: 04/09/2018 by email. The paper copies of the brief should be received by the court on or before 04/18/2018. [512582] [JB] [Entered: 04/11/2018 03:57 PM] (0) |
| Apr 9, 2018 | 56 | APPENDIX FILED for Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Mylan, Inc. and Horizon Pharma, Inc. and Pozen Inc. [50]. Number of Pages: 1020. Service: 04/09/2018 by email. Paper copies should be provided of the confidential version only. [512587] [JB] [Entered: 04/11/2018 04:02 PM] (1020) |
| Apr 2, 2018 | 48 | TENDERED from Cross-Appellants Pozen Inc. and Horizon Pharma, Inc.. Title: REPLY BRIEF. Service: 04/02/2018 by email. [509996] [17-2473] [Charles Collins-Chase] [Entered: 04/02/2018 06:56 PM] (32) |
| Apr 2, 2018 | 49 | REPLY BRIEF FILED for Cross-Appellants Horizon Pharma, Inc. and Pozen Inc. [48]. Number of Pages: 23. Service: 04/02/2018 by email. The paper copies of the brief should be received by the court on or before 04/12/2018. Appendix is due 04/09/2018. [510774] [JB] [Entered: 04/05/2018 08:55 AM] (32) |
| Mar 13, 2018 | 47 | **TEXT ONLY** ORDER granting motion to extend time to file cross-appellant's reply brief [46] filed by Cross-Appellants Pozen Inc. and Horizon Pharma, Inc. Cross-Appellant's reply brief is due 04/02/2018. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [504741] [JB] [Entered: 03/13/2018 04:12 PM] (0) |
| Mar 12, 2018 | 45 | 6 paper copies of the Reply Brief [44] received from Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc. [504140] [SJL] [Entered: 03/12/2018 11:55 AM] (0) |
| Mar 12, 2018 | 46 | MOTION of Cross-Appellants Horizon Pharma, Inc. and Pozen Inc. to extend the time to 04/02/2018 at 11:59 pm to file the cross-appellant's reply brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 03/12/2018 by email. [504399] [James Monroe] [Entered: 03/12/2018 07:45 PM] (9) |
| Mar 5, 2018 | 43 | TENDERED from Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. Title: REPLY BRIEF. Service: 03/05/2018 by email. [502707] [Dan Bagatell] [Entered: 03/05/2018 06:46 PM] (76) |
| Mar 5, 2018 | 44 | REPLY BRIEF FILED for Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc. [43]. Number of Pages: 63. Service: 03/05/2018 by email. The paper copies of the brief should be received by the court on or before 03/14/2018. Cross-Appellant's reply brief is due 03/19/2018. [503322] [JB] [Entered: 03/07/2018 03:59 PM] (76) |
| Feb 1, 2018 | 42 | 6 paper copies of the Opening Response Brief [41] received from Cross-Appellants Horizon Pharma, Inc. and Pozen Inc. [494278] [CFT] [Entered: 02/01/2018 09:28 AM] (0) |
| Jan 23, 2018 | 40 | TENDERED from Cross-Appellants Horizon Pharma, Inc. and Pozen Inc.. Title: OPENING BRIEF. Service: 01/23/2018 by email. [492142] [James Monroe] [Entered: 01/23/2018 11:18 PM] (111) |
| Jan 23, 2018 | 41 | BRIEF FILED for Cross-Appellants Horizon Pharma, Inc. and Pozen Inc. [40]. Number of Pages: 70. Service: 01/23/2018 by email. The paper copies of the brief should be received by the court on or before 02/02/2018. Appellant's reply brief is due 03/05/2018. [493040] [JB] [Entered: 01/26/2018 12:07 PM] (111) |
| Jan 10, 2018 | 39 | **TEXT ONLY** ORDER granting motion to extend time to file cross-appellants principal brief [38] filed by Cross-Appellants Pozen Inc. and Horizon Pharma, Inc. Cross-Appellants principal brief is due 01/23/2018. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [488696] [JB] [Entered: 01/10/2018 01:40 PM] (0) |
| Jan 9, 2018 | 38 | MOTION of Cross-Appellants Horizon Pharma, Inc. and Pozen Inc. to extend the time to 01/23/2018 at 11:59 pm to file the appellee/respondent/cross-appellant's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 01/09/2018 by email. [488514] [James Monroe] [Entered: 01/09/2018 07:34 PM] (9) |
| Dec 15, 2017 | 37 | **TEXT ONLY** ORDER granting motion to extend time to file appellee/respondent/cross-appellant principal brief [36] filed by Cross-Appellants Pozen Inc. and Horizon Pharma, Inc. Cross-Appellants brief is due 01/16/2018. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [482891] [JB] [Entered: 12/15/2017 10:01 AM] (0) |
| Dec 14, 2017 | 36 | MOTION of Cross-Appellants Horizon Pharma, Inc. and Pozen Inc. to extend the time to 01/16/2018 at 11:59 pm to file the appellee/respondent/cross-appellant's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 12/14/2017 by email. [482829] [James Monroe] [Entered: 12/14/2017 07:35 PM] (12) |
| Nov 27, 2017 | 35 | 6 paper copies of the Opening Brief [34] received from Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc. [478252] [CW] [Entered: 11/27/2017 02:54 PM] (0) |
| Nov 14, 2017 | 33 | TENDERED from Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. Title: OPENING BRIEF. Service: 11/14/2017 by email. [475525] [Dan Bagatell] [Entered: 11/14/2017 06:04 PM] (196) |
| Nov 14, 2017 | 34 | BRIEF FILED for Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc. [33]. Number of Pages: 50. Service: 11/14/2017 by email. The paper copies of the brief should be received by the court on or before 11/22/2017. Cross-Appellants Horizon Pharma, Inc. and Pozen Inc. brief is due 12/26/2017. [475895] [JB] [Entered: 11/15/2017 03:34 PM] (196) |
| Nov 9, 2017 | 32 | NOTICE OF DEFICIENCY: The attorney entry of appearance Document No. [30] filed by Appellants Mylan Pharmaceuticals Inc., Mylan, Inc. and Mylan Laboratories Limited was submitted with an incorrect form attached . A corrected entry of appearancet has been filed at entry no 31. [474298] [JB] [Entered: 11/09/2017 12:13 PM] (0) |
| Nov 8, 2017 | 29 | Entry of appearance for Dan L. Bagatell as of counsel for Appellants Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. Service: 11/08/2017 by email. [473907] [Dan Bagatell] [Entered: 11/08/2017 07:50 AM] (2) |
| Nov 8, 2017 | 30 | Entry of appearance for Autumn N. Nero as of counsel for Appellants Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. Service: 11/08/2017 by clerk. [474109] [Autumn Nero] [Entered: 11/08/2017 03:38 PM] (0) |
| Nov 8, 2017 | 31 | Corrected Entry of appearance for Autumn N. Nero as of counsel for Appellants Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. Service: 11/08/2017 by clerk. [474128] [Autumn Nero] [Entered: 11/08/2017 04:21 PM] (2) |
| Oct 18, 2017 | 28 | **TEXT ONLY** ORDER granting motion to extend time to file appellant/petitioner principal brief [27] filed by Appellants Mylan Pharmaceuticals Inc., Dr. Reddy's Laboratories, Ltd., Lupin Pharmaceuticals, Inc., Lupin Ltd., Mylan, Inc., Mylan Laboratories Limited and Dr. Reddy's Laboratories Inc. Brief is due on 11/14/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [468685] [JB] [Entered: 10/18/2017 08:56 AM] (0) |
| Oct 17, 2017 | 26 | Entry of appearance for Andrew T. Dufresne as of counsel for Appellants Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. Service: 10/17/2017 by email. [468513] [Shannon Bloodworth] [Entered: 10/17/2017 03:01 PM] (2) |
| Oct 17, 2017 | 27 | MOTION of Appellants Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories, Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc. to extend the time to 11/14/2017 to file the appellant/petitioner's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 10/17/2017 by email. [468516] [Shannon Bloodworth] [Entered: 10/17/2017 03:06 PM] (12) |
| Oct 12, 2017 | 25 | Amended Certificate of Interest for the Cross-Appellant Pozen Inc.. Service: 10/12/2017 by email. [467406] [Stephen Hash] [Entered: 10/12/2017 03:03 PM] (3) |
| Oct 11, 2017 | 23 | Amended Certificate of Interest for the Cross-Appellant Horizon Pharma, Inc.. Service: 10/11/2017 by email. [467034] [James Monroe] [Entered: 10/11/2017 03:07 PM] (3) |
| Oct 11, 2017 | 24 | Entry of appearance for Charles T. Collins-Chase as of counsel for Cross-Appellant Horizon Pharma, Inc.. Service: 10/11/2017 by email. [467037] [James Monroe] [Entered: 10/11/2017 03:11 PM] (2) |
| Oct 5, 2017 | 22 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a)and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [465748] [JB] [Entered: 10/05/2017 09:29 AM] (0) |
| Sep 8, 2017 | 7 | Docketing Statement for the Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, Ltd.. Service: 09/08/2017 by email. [459624] [Alan Pollack] [Entered: 09/08/2017 10:22 AM] (4) |
| Sep 8, 2017 | 8 | Entry of appearance for Sailesh K. Patel as principal counsel for Appellants Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 09/08/2017 by email. [459841] [Sailesh Patel] [Entered: 09/08/2017 03:46 PM] (2) |
| Sep 8, 2017 | 9 | Certificate of Interest for the Appellants Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 09/08/2017 by email. [459848] [Sailesh Patel] [Entered: 09/08/2017 03:53 PM] (3) |
| Sep 8, 2017 | 10 | Docketing Statement for the Appellants Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 09/08/2017 by email. [459852] [Sailesh Patel] [Entered: 09/08/2017 03:55 PM] (6) |
| Sep 8, 2017 | 11 | Certificate of Interest for the Appellants Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. Service: 09/08/2017 by email. [459903] [Shannon Bloodworth] [Entered: 09/08/2017 05:08 PM] (3) |
| Sep 8, 2017 | 12 | Entry of appearance for Shannon M. Bloodworth as principal counsel for Appellants Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. Service: 09/08/2017 by email. [459904] [Shannon Bloodworth] [Entered: 09/08/2017 05:12 PM] (2) |
| Sep 8, 2017 | 13 | Entry of appearance for Robert D. Swanson as of counsel for Appellants Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. Service: 09/08/2017 by email. [459905] [Shannon Bloodworth] [Entered: 09/08/2017 05:14 PM] (2) |
| Sep 8, 2017 | 14 | Docketing Statement for the Appellants Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. and Mylan, Inc.. Service: 09/08/2017 by email. [459906] [Shannon Bloodworth] [Entered: 09/08/2017 05:16 PM] (2) |
| Sep 8, 2017 | 15 | Entry of appearance for Stephen M. Hash as principal counsel for Cross-Appellant Pozen Inc.. Service: 09/08/2017 by email. [459910] [Stephen Hash] [Entered: 09/08/2017 05:55 PM] (2) |
| Sep 8, 2017 | 16 | Certificate of Interest for the Cross-Appellant Pozen Inc.. Service: 09/08/2017 by email. [459911] [Stephen Hash] [Entered: 09/08/2017 05:56 PM] (2) |
| Sep 8, 2017 | 17 | Docketing Statement for the Cross-Appellant Pozen Inc.. Service: 09/08/2017 by email. [459915] [Stephen Hash] [Entered: 09/08/2017 06:19 PM] (4) |
| Sep 8, 2017 | 18 | Entry of appearance for Jeffrey S. Gritton as of counsel for Cross-Appellant Pozen Inc.. Service: 09/08/2017 by email. [459917] [Jeffrey Gritton] [Entered: 09/08/2017 06:24 PM] (2) |
| Sep 8, 2017 | 19 | Entry of appearance for James B. Monroe as principal counsel for Cross-Appellant Horizon Pharma, Inc.. Service: 09/08/2017 by email. [459919] [James Monroe] [Entered: 09/08/2017 06:31 PM] (2) |
| Sep 8, 2017 | 20 | Certificate of Interest for the Cross-Appellant Horizon Pharma, Inc.. Service: 09/08/2017 by email. [459920] [James Monroe] [Entered: 09/08/2017 06:35 PM] (2) |
| Sep 8, 2017 | 21 | Docketing Statement for the Cross-Appellant Horizon Pharma, Inc.. Service: 09/08/2017 by email. [459921] [James Monroe] [Entered: 09/08/2017 06:38 PM] (4) |
| Sep 5, 2017 | 6 | Entry of appearance for Alan H. Pollack as principal counsel for Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, Ltd.. Service: 09/05/2017 by email. [458591] [Alan Pollack] [Entered: 09/05/2017 02:04 PM] (2) |
| Aug 30, 2017 | 3 | Entry of appearance for Stuart D Sender as of counsel for Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, Ltd.. Service: 08/30/2017 by email. [457776] [Stuart Sender] [Entered: 08/30/2017 02:53 PM] (2) |
| Aug 30, 2017 | 4 | Certificate of Interest for the Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, Ltd.. Service: 08/30/2017 by email. [457777] [Stuart Sender] [Entered: 08/30/2017 02:54 PM] (3) |
| Aug 30, 2017 | 5 | Transcript Purchase Order Form for the Appellants Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, Ltd. indicating that a transcript is already on file. Service: 08/30/2017 by email. [457778] [Stuart Sender] [Entered: 08/30/2017 02:56 PM] (2) |
| Aug 25, 2017 | 1 | Appeal docketed. Received: 08/21/2017. [456599]Entry of Appearance due 09/08/2017. Certificate of Interest is due on 09/08/2017. Docketing Statement due 09/08/2017. Appellant/Petitioner's brief is due 10/24/2017. [JB] [Entered: 08/25/2017 10:51 AM] (82) |
| Aug 25, 2017 | 2 | Note to file: The following cases are consolidated: 17-2473 Lead with 17-2481,17-2484, 17-2486, 17-2487, 17-2488 (MEMBER CASES) and 17-2489, 17-2491, 17-2492, 17-2493 (CROSS-APPEALS). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [456764] [JB] [Entered: 08/25/2017 03:08 PM] (0) |
